- Home
- HSDT vs ONCO Comparison
HSDT vs ONCO Comparison
Compare HSDT & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HSDT | ONCO |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.6M | 4.3M |
| IPO Year | N/A | 2022 |
Fundamental Metrics
Financial Performance| Metric | HSDT | ONCO |
|---|---|---|
| Price | $3.42 | $2.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 713.8K | 36.1K |
| Earning Date | 11-18-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $941,000.00 | ★ $1,223,751.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $75.13 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 87.45 | N/A |
| 52 Week Low | $2.83 | $2.10 |
| 52 Week High | $1,200.00 | $179.35 |
Technical Indicators
Market Signals| Indicator | HSDT | ONCO |
|---|---|---|
| Relative Strength Index (RSI) | 34.42 | 40.85 |
| Support Level | $3.83 | $2.53 |
| Resistance Level | $4.32 | $3.22 |
| Average True Range (ATR) | 0.41 | 0.31 |
| MACD | 0.19 | 0.01 |
| Stochastic Oscillator | 22.13 | 14.02 |
Price Performance
Historical ComparisonAbout HSDT Helius Medical Technologies Inc. (DE)
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.